Tight-lipped Merck KGaA to remedy 'inefficiency' before investing in growth
This article was originally published in Scrip
There was disappointment today for those who were hoping that during its annual results conference Merck KGaA would provide further details of the "efficiency measures" announced last month. The company remained tight-lipped about the two-year restructuring programme, which will involve yet to be defined "workforce reductions across all divisions and geographies" (scripintelligence.com, 24 February 2012). The company said it would not go into detail about these measures until it announced its first-quarter results on 15 May.
You may also be interested in...
Industry leaders share their expectations around COVID-19 for the coming year. Further product development and vaccine rollout will be key themes in 2021. Equitable supply and addressing the mental health challenges associated with lockdowns also loom large.
French phama pioneers sustainable finance in pharma with $8bn in new credit facilities tied to polio eradication and carbon reduction.
Sanofi pioneers sustainable finance in pharma with $8bn in new credit facilities tied to polio eradication and carbon reduction.